- Trials with a EudraCT protocol (121)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
121 result(s) found for: Hepatic encephalopathy.
Displaying page 1 of 7.
EudraCT Number: 2012-000931-20 | Sponsor Protocol Number: TIPS-EE | Start Date*: 2012-05-25 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: EFFECT OF ALBUMIN INFUSION TO PREVENT OVERT HEPATIC ENCEPHALOPATHY AFTER TRANSGIUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT (TIPS). | |||||||||||||
Medical condition: PREVENTION OF HEPATIC ENCEPHALOPATHY IN CIRRHOTIC PATIENTS WHO UNDERGO TIPS PLACEMENT | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000563-81 | Sponsor Protocol Number: EME | Start Date*: 2014-07-29 | |||||||||||
Sponsor Name:FUNDACION PUBLICA ANDALUZA PARA LA GESTION DE LA INVESTIGACION EN SALUD DE SEVILLA | |||||||||||||
Full Title: Metformin treatment of minimal hepatic encephalopathy in patients with liver cirrhosis | |||||||||||||
Medical condition: minimal hepatic encephalopathy in patients with liver cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004809-33 | Sponsor Protocol Number: BETA | Start Date*: 2015-03-09 | ||||||||||||||||
Sponsor Name:Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | ||||||||||||||||||
Full Title: Albumin infusion effects in patients with cirrhosis hepatic encephalopathy | ||||||||||||||||||
Medical condition: hepatic encephalopathty | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-003817-32 | Sponsor Protocol Number: LOLA-Merz:WMDHP39937 | Start Date*: 2013-01-08 | |||||||||||
Sponsor Name:Imperial College London | |||||||||||||
Full Title: Brain muscle axis during treatment of hepatic encephalopathy with L-ornithine L-aspartate | |||||||||||||
Medical condition: Hepatic Encephalopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-005412-10 | Sponsor Protocol Number: OCR002-HE209 | Start Date*: 2014-08-25 | |||||||||||
Sponsor Name:Ocera Therapeutics Inc | |||||||||||||
Full Title: Multicenter, Randomized Phase 2B Study to Evaluate the Efficacy, Safety and Tolerability of OCR-002 (ornithine phenylacetate) in Hospitalized Patients with Cirrhosis and Associated Hyperammonemi... | |||||||||||||
Medical condition: Hepatic encephalopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: EE (Completed) CZ (Completed) AT (Completed) HU (Completed) IT (Completed) DE (Completed) NL (Completed) BE (Completed) DK (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002924-11 | Sponsor Protocol Number: LOLAbiome | Start Date*: 2023-01-09 | ||||||||||||||||
Sponsor Name:CBmed GmbH | ||||||||||||||||||
Full Title: An observational study on the effect of L-ornithine-L-aspertate (LOLA) on the Flavonifractor abundance in the gut microbiome in liver cirrhosis | ||||||||||||||||||
Medical condition: Liver cirrhosis with covert or overt hepatic encephalopathy (grade 0-2) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004708-20 | Sponsor Protocol Number: RIFSYS | Start Date*: 2014-03-27 | ||||||||||||||||
Sponsor Name:King's College London
[...]
1. King's College London
2. King's College Hospital NHS Foundation Trust |
||||||||||||||||||
Full Title: A placebo controlled single centre double blind randomised trial to investigate the efficacy of rifaximin versus placebo in improving systemic inflammation and neutrophil malfunction in patients wi... | ||||||||||||||||||
Medical condition: Cirrhosis and chronic hepatic encephalopathy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-003376-21 | Sponsor Protocol Number: ALFAE | Start Date*: 2008-11-14 | |||||||||||
Sponsor Name:Servicio Hepatología. Hospital Vall d'Hebron | |||||||||||||
Full Title: EFECTOS DE LA ADMINISTRACIÓN DE ALBÚMINA EN PACIENTES CON CIRROSIS Y ENCEFALOPATIA HEPÁTICA AGUDA | |||||||||||||
Medical condition: Encefalopatía hepática en pacientes con cirrosis hepática. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005969-13 | Sponsor Protocol Number: AXA1665-101 | Start Date*: 2021-08-11 | ||||||||||||||||
Sponsor Name:Axcella Health, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of AXA1665 in Subjects With Liver Cirrhosis and Prior Overt Hepatic Encephalopathy (EM... | ||||||||||||||||||
Medical condition: Overt Hepatic Encephalopathy in Subjects with Liver Cirrhosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) PL (Completed) HU (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004323-37 | Sponsor Protocol Number: PEARL-trial | Start Date*: 2019-06-06 | ||||||||||||||||||||||||||
Sponsor Name:Academic Medical Centre | ||||||||||||||||||||||||||||
Full Title: Prevention of hepatic Encephalopathy by Administration of Rifaximin and Lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt: a multi-c... | ||||||||||||||||||||||||||||
Medical condition: post-TIPS Hepatic Encephalopathy (HE) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-005008-16 | Sponsor Protocol Number: STOPPIT-01 | Start Date*: 2021-03-08 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Stop of proton-pump inhibitor treatment in patients with liver cirrhosis – a double-blind, placebo-controlled trial | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Liver cirrhosis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-003651-30 | Sponsor Protocol Number: UCAB-CT-02 | Start Date*: 2016-12-01 |
Sponsor Name:Umecrine Cognition AB | ||
Full Title: Safety, tolerability and pharmacokinetics (PKs) of multiple oral doses of GR3027 in healthy male volunteers and single and multiple doses in patients with cirrhosis. Preliminary efficacy in cirrhot... | ||
Medical condition: Hepatic encephalopathy (HE) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DK (Completed) FI (Completed) PL (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020657-14 | Sponsor Protocol Number: ALF-5755_P2_ALF | Start Date*: 2011-07-04 | |||||||||||
Sponsor Name:Alfact Innovation | |||||||||||||
Full Title: A multicentre, double-blind, randomized, placebo-controlled study to evaluate the efficacy and the safety of ALF-5755 in patients with nonacetaminophen severe acute hepatitis and early stage acute ... | |||||||||||||
Medical condition: Acute liver failure | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000837-39 | Sponsor Protocol Number: CCD01 | Start Date*: 2007-08-15 | |||||||||||
Sponsor Name:Cytonet GmbH & Co. KG | |||||||||||||
Full Title: Open, randomized, prospective, controlled, multicentre study to evaluate the efficacy and safety of multiple intraportal applications of liver cell suspension in patients with acute liver failure n... | |||||||||||||
Medical condition: Acute Liver Failure Subgroups of patients with indications falling under ICD classification codes:K70.4, K71, K72, K75, K76, K77 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003349-41 | Sponsor Protocol Number: ERASMECMI | Start Date*: 2013-10-03 | |||||||||||
Sponsor Name:Erasme hospital | |||||||||||||
Full Title: what are the optimal doses of cefuroxime for cirrhotic patients? | |||||||||||||
Medical condition: Cirrhotic patients with infection requiring treatment with cefuroxime | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-001177-32 | Sponsor Protocol Number: HEP101 | Start Date*: 2016-08-09 | ||||||||||||||||
Sponsor Name:Promethera Biosciences | ||||||||||||||||||
Full Title: Multicenter Phase II Safety and Preliminary Efficacy Study of 2 dose regimens of HepaStem in Patients with Acute on Chronic Liver Failure | ||||||||||||||||||
Medical condition: The study will recruit cirrhotic patients who are hospitalized for Acute-on-chronic liver failure (ACLF) or Acute Decompensation at risk of developing ACLF. ACLF combines an acute deterioration of... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) FR (Completed) ES (Completed) BG (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-005628-13 | Sponsor Protocol Number: IRRB/34/12 | Start Date*: 2012-12-19 | ||||||||||||||||||||||||||
Sponsor Name:ISTITUTO MEDITERRANEO PER I TRAPIANTI E TERAPIE AD ALTA SPECIALIZZAZIONE | ||||||||||||||||||||||||||||
Full Title: Transplantation of Human Fetal Liver Cells for the Treatment of Patients with Decompensated Liver Cirrhosis | ||||||||||||||||||||||||||||
Medical condition: liver cirrhosis | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001449-42 | Sponsor Protocol Number: VITDCirrhosis2012 | Start Date*: 2014-10-03 | |||||||||||
Sponsor Name:Medizinische Universität Graz, Kl. Abt. f. Endokrinoloie u. Stoffwechsel & Kl. Abt. f. Gastroenterologie u. Hepatologie | |||||||||||||
Full Title: A randomized, double-blind, placebo controlled trial to evaluate vitamin D supplementation on serum 25 hydroxy- vitamin D level in cirrhotic patients | |||||||||||||
Medical condition: decompensated and compensated liver cirrhosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004373-50 | Sponsor Protocol Number: 369852 | Start Date*: 2021-04-08 | |||||||||||
Sponsor Name:Aarhus University Hospital | |||||||||||||
Full Title: Effect of treatment with Semaglutide on cognitive function, neuroinflammation and hepatic nitrogen metabolism in patients with non-alcoholic steatohepatitis: A randomized placebo-controlled trial | |||||||||||||
Medical condition: Non-alcoholic steatohepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000819-25 | Sponsor Protocol Number: DS102A-05-AH1 | Start Date*: 2019-01-31 | |||||||||||
Sponsor Name:Afimmune | |||||||||||||
Full Title: A Randomised, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Orally Administered DS102 in Patients with Severe Acute Decompensated Alcoholic Hepatitis. | |||||||||||||
Medical condition: Severe Acute Decompensated Alcoholic Hepatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) LV (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
